Hologic stock trades near 52-week high on steady demand

Hologic stock is trading close to its 52-week high as investors weigh solid healthcare equipment demand against a rich valuation and a full earnings calendar for fiscal year 2026.

Hologic (ISIN US4364401012) stock is quoted at 76.07 USD as of September 6, 2026 on Nasdaq, close to the upper end of its 52-week range between 51.90 USD and 76.07 USD according to market data compiled by MarketBeat. The company, a specialist in diagnostic and surgical technologies, carries a market capitalization of about 16.97 billion USD as of September 6, 2026, placing it in the mid-cap segment of the US healthcare equipment space.

Stock near yearly high with solid valuation

According to MarketBeat data for Hologic as of September 6, 2026, the share price around 76.07 USD compares with a 52-week low of 51.90 USD and a 52-week high of 76.07 USD, meaning the stock currently trades at the very top of its yearly range. With a reported price to earnings ratio of 31.67 based on recent earnings, the valuation reflects the market’s expectation of continued earnings stability in healthcare equipment and supplies. For investors, this combination of a mid-cap market value of roughly 16.97 billion USD and a high-teens to low-thirties earnings multiple sets the context for returns expectations in fiscal year 2026.

The same MarketBeat overview lists Hologic in the healthcare equipment and supplies industry within the broader healthcare sector, with the current symbol HOLX on Nasdaq and a fiscal year end of September 30, 2026. The calendar in this data shows the last earnings event on January 29, 2026, tied to the company’s fiscal reporting cycle for the year ending September 30, 2026. While detailed revenue and profit figures for that reporting date are not broken out in this snapshot, the price to earnings ratio of 31.67 implies that the market is capitalizing the company’s trailing net income at more than thirty times its current level.

Earnings cycle and analyst expectations

MarketBeat’s consensus figures indicate an average analyst price target of 79.13 USD for Hologic, with individual targets spanning from 76.00 USD on the low side to 90.00 USD on the high side. This range suggests a potential upside of around 4.1% from the current share price to the average target, and a larger move of about 18.4% to the highest published target of 90.00 USD, based on data as of September 6, 2026. The consensus rating in this overview is described as Hold, signaling that analysts broadly see the stock as fairly valued relative to fundamentals and growth prospects.

For the fiscal year ending September 30, 2026, Hologic’s earnings calendar implies regular quarterly updates, with the last reported earnings event dated January 29, 2026 in the MarketBeat listing. In the absence of more granular figures in this specific dataset, the implied trailing earnings used for the 31.67 price to earnings ratio form a key reference point for valuation. In practice, if earnings per share were, for example, around 2.40 USD over the trailing twelve months, a share price near 76.07 USD would be consistent with a multiple slightly above 31 times earnings. This kind of earnings level would align with a mid-teens profit margin for a company with multi-billion dollar annual revenue, typical for established healthcare equipment suppliers.

Diagnostic portfolio underpins business model

Hologic’s business model is built around medical devices and diagnostic systems used primarily in women’s health, including imaging systems, diagnostic tests and surgical products. While specific segment revenues for the most recent quarter are not detailed in the MarketBeat snapshot, historically the company has generated a substantial portion of its revenue from diagnostics and breast health solutions. In a typical year, individual segments such as molecular diagnostics and breast imaging can represent hundreds of millions of dollars in revenue, often with mid-teens percent growth in key technology lines when new platforms and assays are adopted in clinical practice.

The company’s focus on recurrent revenue from consumables and service contracts, alongside capital equipment sales, can provide a relatively stable stream of cash flows. For investors, this makes Hologic sensitive not only to hospital and laboratory capital budgets but also to testing volumes and reimbursement trends. As healthcare systems continue to prioritize early detection, demand for high-quality diagnostic systems tends to support the installed base and ongoing upgrade cycles, which in turn can stabilize revenue and earnings across fiscal years.

Hologic stock valuation and investor perspective

With Hologic stock trading at 76.07 USD as of September 6, 2026, the market assigns the company a mid-cap market capitalization of about 16.97 billion USD and a trailing price to earnings ratio around 31.67, according to MarketBeat. The share price at the top of its 51.90 USD to 76.07 USD 52-week range shows that the stock has moved significantly higher over the last twelve months, reflecting investor confidence in the company’s role in the healthcare equipment and supplies industry. For retail investors, the key questions now are how earnings will develop over the remainder of fiscal year 2026 and whether future guidance and analyst revisions will support further upside toward the average price target of 79.13 USD.

Hologic stock at a glance

• Company: Hologic, Inc.
• ISIN: US4364401012
• Ticker: HOLX
• Trading venue: NASDAQ
• Price (as of September 6, 2026): 76.07 USD
• Market capitalization: 16.97 billion USD (as of September 6, 2026)
• Sector / Industry: Healthcare / Healthcare equipment and supplies
• Index membership: S&P 500